AskMuncher
5年前
$OHCS Optimus Healthcare Services Announces FINRA Approval for Corporate Symbol Change
Press Release | 06/15/2021
NEW YORK, NY / ACCESSWIRE / June 15, 2021 / Optimus Healthcare Services, Inc. (OTC PINK:OHCS), a holding company focused on creating a network of innovative healthcare entities that advance clinical research, disease management and improve physician/patient interactions announced today that it received approval notification from the Financial Industry Regulatory Authority (FINRA) for a corporate symbol change. The symbol for Optimus Healthcare Services will change to "OHCS" and take effect at the open of business on June 16, 2021.
"The FINRA approval of the symbol change is a further step in our effort to appropriately align our business identification with our focus on building the Optimus brand," said Marc Wiener, Optimus Healthcare Services CEO. "In addition to the imagery represented by our trading symbol change to accurately reflect our platform, we continue the mission to evaluate and acquire healthcare-related businesses that have the potential to be transformative in their area of expertise."
About Optimus
Optimus Healthcare Services is focused on creating a network of innovative healthcare companies that advance clinical research, disease management and improve physician/patient interactions. A prime focus will include acquiring controlling interests in a variety of healthcare-related businesses.
Caution Concerning Forward-Looking Statements:
This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to Optimus and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning Optimus's business are described in Periodic and Current Reports filed with the Securities and Exchange Commission. Optimus is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Dan Cohen
President, Optimus Healthcare Services
dlc@painscript.com
202-329-1825
SOURCE: Optimus Healthcare Services, Inc.
View source version on accesswire.com:
https://www.accesswire.com/651838/Optimus-Healthcare-Services-Announces-FINRA-Approval-for-Corporate-Symbol-Change
AskMuncher
5年前
$HOPS Optimus Healthcare Services Announces FINRA Approval for Corporate Name Change
Press Release | 06/03/2021
Industry Veteran Cliff Saffron named Chief Financial Officer and General Counsel
NEW YORK, NY / ACCESSWIRE / June 3, 2021 / Optimus Healthcare Services, Inc. (OTC PINK:HOPS) announced today that it received approval notification from the Financial Industry Regulatory Authority (FINRA) for a corporate name change. The entity formerly known as "Between Dandelions" will begin doing business as of June 3, 2021, as Optimus Healthcare Services, Inc. The symbol for Optimus Healthcare Services will remain as "HOPS."
"The FINRA approval is an important element of our growth strategy which is focused on leveraging the synergies within Optimus to enhance shareholder value," said Marc Wiener, Optimus Healthcare Services CEO. "In addition to the symbolism of the name change to accurately reflect the emphasis of our platform, additional efforts are focused on the continued evaluation of potential acquisitions of healthcare-related businesses. Other management activities include the up-listing of Optimus to a more senior financial platform, when appropriate, and the continued expansion of our Board and Management with key thought and business leaders."
In addition, Kenneth Orr, Executive Chair of Optimus Healthcare Services, announced that long-time legal counsel and industry executive Cliff Saffron has joined the company to serve as the Chief Financial Officer and General Counsel. Mr. Saffron has assumed responsibilities related to aligning corporate growth and the long-term strategic vision for Optimus Healthcare Services.
About Optimus
Optimus Healthcare Services is focused on creating a network of innovative healthcare companies that advance clinical research, disease management and improve physician/patient interactions. A prime focus will include acquiring controlling interests in a variety of healthcare-related businesses.
Caution Concerning Forward Looking Statements:
This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to Optimus and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning Optimus's business are described in Periodic and Current Reports filed with the Securities and Exchange Commission. Optimus is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Marc Wiener
CEO Optimus Healthcare Services
mwiener@researchcra.com
516-669-6555
Dan Cohen
President, Optimus Healthcare Services
dlc@painscript.com
202-329-1825
SOURCE: Optimus HealthCare Services, Inc.
View source version on accesswire.com:
https://www.accesswire.com/650308/Optimus-Healthcare-Services-Announces-FINRA-Approval-for-Corporate-Name-Change
AskMuncher
5年前
$HOPS Between Dandelions, Inc. Announces Merger with Optimus Healthcare Services, Inc.
Press Release | 12/29/2020
NEW YORK, NY / ACCESSWIRE / December 29, 2020 / Between Dandelions Inc (OTC PINK:HOPS) announced today the closing of a merger with Optimus Healthcare Services, Inc. ("Optimus" or "Company").
Optimus, a company formed in 2020, controlled by KORR Acquisitions Group, Inc. ("KORR"), recently acquired control of Clinical Research Alliance, Inc. ("CRA"). Optimus was a portfolio company of KORR and as of the closing, KORR is now the controlling shareholder of Between Dandelions Inc. Between Dandelions Inc. will change its name to Optimus Healthcare Services Inc.
Optimus will focus on healthcare-related services.
The Company has appointed a new CEO, Marc Wiener. Prior to joining Optimus, Mr. Wiener was the founder of Orphan Pharmacy Services, which was sold in 2020, the co-founder of Linden Care Services, which sold to Belhealth Investment Partners in 2013, and Vitality Pharmaceutical Services, which sold to BioScrip in 2002.
Mr. Wiener graduated from St. John's University in 1989 with a degree in Pharmacy.
"I was happy for our shareholders that we had a successful sale our beer assets and were able to distribute a special dividend to our shareholders last year. We have been looking for an opportunity to bring additional value to our shareholders and believe we have done just that in this merger with Optimus. I am excited to work with KORR and the team of CRA," commented Sean Spiegelman.
About Clinical Research Alliance ("CRA")
CRA was founded by Dr. Francis Arena and Dr. Morton Coleman, both of whom are respected as among the top oncologists in the United States. Dr. Coleman and Dr. Arena will continue their affiliation with CRA, and Marc Wiener and industry veteran David Bensol take operational control in CRA's planned expansion.
CRA brings the clinician and patient together for clinical trials - all within the comforts of community-based offices without the stress of travel or changing of doctors, providing pristine clinical data designed to facilitate and advance the treatment of disease. CRA is dedicated to providing our community oncologists the support and vital infrastructure necessary to gather data and administer these studies by our mobile task force of research nurses and clinical research coordinators. This will ensure the ability to provide pristine study data and the appropriate documentation of clinical outcomes in a controlled atmosphere without additional work for your staff. Our proven method of centralized regulatory monitoring and contractual services will expedite the research process resulting in quality data while following the guidelines of Good Clinical Practices.
A centralized uniform approach to the implementation and supervision of clinical trials.
Direct access with your physician office providing the necessary mobile staff
The most dynamic of studies often involving new treatment strategies to combat cancer.
(https://www.clinicalresearchalliance.org/)
CRA is changing the paradigm of how clinical research is done. CRA has multiple research sites throughout the tri-state area (New York, New Jersey, and Connecticut). CRA's list of Alliance physicians and locations of sites continues to grow and expand.
Board of Directors
Effective today, the board of directors for Between Dandelions, Inc. shall include:
Marc Wiener, CEO and board member (see bio above)
Kenneth Orr, Executive Chairman
Mr. Orr is Executive Chairman of the Company and also the Executive Chairman of Charge Enterprises.
Since founding KORR, Mr. Orr has been an activist investor pushing to drive stakeholder value at undervalued public companies. Mr. Orr's most recent activist campaigns include: Sanderson Farms, encouraging the board to engage in a share buyback program, The Andersons, organizing a takeover bid by a partner of KORR for $1.5 billion, Argan Inc., pushing a share buyback and a special dividend rewarding long-term shareholders, GoPro, shifting its sales channel from retail-focused to digital, and Medallion Financial, de-consolidating a trust and issuing unsecured notes.
Mr. Orr acquired Herold Securities in 1994 and renamed the firm First Cambridge Securities ("FCS"). FCS established offices in New York City and Los Angeles. As Chief Executive Officer, Kenny built the firm to over 400 employees with more than 15,000 clients. Notable underwritings and/or investment focuses included Rentway, which later sold to Rent-A-Center in 2003, and Ivax Corporation, which sold to Teva in 2005, creating the largest generic drug manufacturer in the world.
Mr. Orr is a graduate of Tufts University. Mr. Orr completed case studies in finance at Harvard Business School, and value investing at Columbia Business School. Mr. Orr holds a Series 65 - Uniform Investment Advisor Law Exam
Philip Scala, CEO of Pathfinder Consultants International, Inc. ("Pathfinder"). Prior to forming Pathfinder, Mr. Scala served the United States both as a Commissioned Officer in the US Army for five years followed by his service in the New York SWAT Team, followed by 29 years of service with the FBI. Mr. Scala has been the recipient of numerous commendations and awards for outstanding service, notably the FBI Shield of Bravery, as a group commendation, as the SWAT team leader of the Al-Qaeda Bomb Factory Raid, on June 3, 1993. Mr. Scala was selected as a Supervisory Special Agent for the Gambino La Cosa Nostra Squad (C-16). During his tenure, the squad successfully investigated and prosecuted the Mob infiltration of Wall Street, the New York Waterfront investigation, "Murder Incorporated," labor racketeering, the NY Construction Industry, dismantlement of the Gambino family in NY and Sicily, the NBA referee case, and the largest consumers' fraud ($1 billion) in US history, which involved the mob's infiltration of the internet, telecommunications, and banking industries.
James Murphy, CEO of Sutton Associates, a global investigative and research firm. Mr. Murphy is a former Special Agent with the FBI, and former president of Society of Former Special Agents of the Federal Bureau of Investigation. The film, "Dog Day Afternoon" about a bank robbery in 1972 and the 15-hour standoff that followed is based upon Agent Murphy's real life heroism that ended the standoff.
Justin Deutsch has over 20 years in the investment business. He joined Weybosset Research & Management, LLC in October 2014 as a portfolio manager and is responsible for investing over $300 million in investor capital. Prior to joining the firm, he was an equity analyst and trader at Bay Crest Partners for five years. Before Bay Crest, Justin worked as head trader and portfolio manager for Horn Capital Management.
Michael Pruitt founded in 1999, Avenel Financial Group, a boutique merchant banking firm. Mr. Pruitt formed Chanticleer Holdings, now Amergent Hospitality Group, which commenced operations in June 2005 with him as Chairman of the Board of Directors and CEO, roles he continues to serve today. In January 2011, Mr. Pruitt became a director of the board of Hooters of America, LLC and was early investor/board member in Appalachian Mountain Brewery which was sold to Craft Brew Alliance (Nasdaq:BREW) in 2018. Mr. Pruitt received a Bachelor of Arts degree from Coastal Carolina University in Conway, South Carolina, where he played on the 1982 and 83 World Series Baseball teams.
James Hartmann was a Managing Director, Chief Compliance Officer for Arena Investors LP and its private placement broker-dealer, Arena Financial Services LLC. Earlier in his career, Mr. Hartmann served as CCO for Prudential Public Fixed Income, and UBS Alternative & Quantitative Investments. Mr. Hartmann has also worked as an in-house consultant for assurance clients of PricewaterhouseCoopers and Ernst & Young.
Mr. Hartmann began his career at the U.S. Securities & Exchange Commission's New York Regional Office in 1990.
Path Forward
The Company expects to update its financials, name change and symbol change as soon as possible.
About Optimus
Optimus will focus on acquiring controlling interests in profitable healthcare-related businesses. Between Dandelions Inc. will file for a name change to Optimus Healthcare Services, Inc. as soon as possible.
Safe Harbor Statement Information in this news release may contain statements about future expectations, plans, prospects or performance of Between Dandelions, Inc. that constitute forward-looking statements for purposes of the safe harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Between Dandelions, Inc. cautions you that any forward-looking information provided by or on behalf of Between Dandelions, Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Between Dandelions, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Between Dandelions, Inc.'s control. In addition to those discussed in Between Dandelions, Inc.'s press releases, public filings, and statements by Between Dandelions, Inc.'s management, including, but not limited to, Between Dandelions, Inc.'s estimate of the sufficiency of its existing capital resources, Between Dandelions, Inc.'s ability to raise additional capital to fund future operations, Between Dandelions, Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Between Dandelions, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Between Dandelions, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT:
Optimus HealthCare Services, Inc
Marc Wiener
mwiener@researchcra.com
1-855-737-2873
SOURCE: Between Dandelions, Inc.
View source version on accesswire.com:
https://www.accesswire.com/622457/Between-Dandelions-Inc-Announces-Merger-with-Optimus-Healthcare-Services-Inc
AskMuncher
5年前
$HOPS Between Dandelions, Inc. Announces Merger with Optimus Healthcare Services, Inc.
Press Release | 12/29/2020
NEW YORK, NY / ACCESSWIRE / December 29, 2020 / Between Dandelions Inc (OTC PINK:HOPS) announced today the closing of a merger with Optimus Healthcare Services, Inc. ("Optimus" or "Company").
Optimus, a company formed in 2020, controlled by KORR Acquisitions Group, Inc. ("KORR"), recently acquired control of Clinical Research Alliance, Inc. ("CRA"). Optimus was a portfolio company of KORR and as of the closing, KORR is now the controlling shareholder of Between Dandelions Inc. Between Dandelions Inc. will change its name to Optimus Healthcare Services Inc.
Optimus will focus on healthcare-related services.
The Company has appointed a new CEO, Marc Wiener. Prior to joining Optimus, Mr. Wiener was the founder of Orphan Pharmacy Services, which was sold in 2020, the co-founder of Linden Care Services, which sold to Belhealth Investment Partners in 2013, and Vitality Pharmaceutical Services, which sold to BioScrip in 2002.
Mr. Wiener graduated from St. John's University in 1989 with a degree in Pharmacy.
"I was happy for our shareholders that we had a successful sale our beer assets and were able to distribute a special dividend to our shareholders last year. We have been looking for an opportunity to bring additional value to our shareholders and believe we have done just that in this merger with Optimus. I am excited to work with KORR and the team of CRA," commented Sean Spiegelman.
About Clinical Research Alliance ("CRA")
CRA was founded by Dr. Francis Arena and Dr. Morton Coleman, both of whom are respected as among the top oncologists in the United States. Dr. Coleman and Dr. Arena will continue their affiliation with CRA, and Marc Wiener and industry veteran David Bensol take operational control in CRA's planned expansion.
CRA brings the clinician and patient together for clinical trials - all within the comforts of community-based offices without the stress of travel or changing of doctors, providing pristine clinical data designed to facilitate and advance the treatment of disease. CRA is dedicated to providing our community oncologists the support and vital infrastructure necessary to gather data and administer these studies by our mobile task force of research nurses and clinical research coordinators. This will ensure the ability to provide pristine study data and the appropriate documentation of clinical outcomes in a controlled atmosphere without additional work for your staff. Our proven method of centralized regulatory monitoring and contractual services will expedite the research process resulting in quality data while following the guidelines of Good Clinical Practices.
A centralized uniform approach to the implementation and supervision of clinical trials.
Direct access with your physician office providing the necessary mobile staff
The most dynamic of studies often involving new treatment strategies to combat cancer.
(https://www.clinicalresearchalliance.org/)
CRA is changing the paradigm of how clinical research is done. CRA has multiple research sites throughout the tri-state area (New York, New Jersey, and Connecticut). CRA's list of Alliance physicians and locations of sites continues to grow and expand.
Board of Directors
Effective today, the board of directors for Between Dandelions, Inc. shall include:
Marc Wiener, CEO and board member (see bio above)
Kenneth Orr, Executive Chairman
Mr. Orr is Executive Chairman of the Company and also the Executive Chairman of Charge Enterprises.
Since founding KORR, Mr. Orr has been an activist investor pushing to drive stakeholder value at undervalued public companies. Mr. Orr's most recent activist campaigns include: Sanderson Farms, encouraging the board to engage in a share buyback program, The Andersons, organizing a takeover bid by a partner of KORR for $1.5 billion, Argan Inc., pushing a share buyback and a special dividend rewarding long-term shareholders, GoPro, shifting its sales channel from retail-focused to digital, and Medallion Financial, de-consolidating a trust and issuing unsecured notes.
Mr. Orr acquired Herold Securities in 1994 and renamed the firm First Cambridge Securities ("FCS"). FCS established offices in New York City and Los Angeles. As Chief Executive Officer, Kenny built the firm to over 400 employees with more than 15,000 clients. Notable underwritings and/or investment focuses included Rentway, which later sold to Rent-A-Center in 2003, and Ivax Corporation, which sold to Teva in 2005, creating the largest generic drug manufacturer in the world.
Mr. Orr is a graduate of Tufts University. Mr. Orr completed case studies in finance at Harvard Business School, and value investing at Columbia Business School. Mr. Orr holds a Series 65 - Uniform Investment Advisor Law Exam
Philip Scala, CEO of Pathfinder Consultants International, Inc. ("Pathfinder"). Prior to forming Pathfinder, Mr. Scala served the United States both as a Commissioned Officer in the US Army for five years followed by his service in the New York SWAT Team, followed by 29 years of service with the FBI. Mr. Scala has been the recipient of numerous commendations and awards for outstanding service, notably the FBI Shield of Bravery, as a group commendation, as the SWAT team leader of the Al-Qaeda Bomb Factory Raid, on June 3, 1993. Mr. Scala was selected as a Supervisory Special Agent for the Gambino La Cosa Nostra Squad (C-16). During his tenure, the squad successfully investigated and prosecuted the Mob infiltration of Wall Street, the New York Waterfront investigation, "Murder Incorporated," labor racketeering, the NY Construction Industry, dismantlement of the Gambino family in NY and Sicily, the NBA referee case, and the largest consumers' fraud ($1 billion) in US history, which involved the mob's infiltration of the internet, telecommunications, and banking industries.
James Murphy, CEO of Sutton Associates, a global investigative and research firm. Mr. Murphy is a former Special Agent with the FBI, and former president of Society of Former Special Agents of the Federal Bureau of Investigation. The film, "Dog Day Afternoon" about a bank robbery in 1972 and the 15-hour standoff that followed is based upon Agent Murphy's real life heroism that ended the standoff.
Justin Deutsch has over 20 years in the investment business. He joined Weybosset Research & Management, LLC in October 2014 as a portfolio manager and is responsible for investing over $300 million in investor capital. Prior to joining the firm, he was an equity analyst and trader at Bay Crest Partners for five years. Before Bay Crest, Justin worked as head trader and portfolio manager for Horn Capital Management.
Michael Pruitt founded in 1999, Avenel Financial Group, a boutique merchant banking firm. Mr. Pruitt formed Chanticleer Holdings, now Amergent Hospitality Group, which commenced operations in June 2005 with him as Chairman of the Board of Directors and CEO, roles he continues to serve today. In January 2011, Mr. Pruitt became a director of the board of Hooters of America, LLC and was early investor/board member in Appalachian Mountain Brewery which was sold to Craft Brew Alliance (Nasdaq:BREW) in 2018. Mr. Pruitt received a Bachelor of Arts degree from Coastal Carolina University in Conway, South Carolina, where he played on the 1982 and 83 World Series Baseball teams.
James Hartmann was a Managing Director, Chief Compliance Officer for Arena Investors LP and its private placement broker-dealer, Arena Financial Services LLC. Earlier in his career, Mr. Hartmann served as CCO for Prudential Public Fixed Income, and UBS Alternative & Quantitative Investments. Mr. Hartmann has also worked as an in-house consultant for assurance clients of PricewaterhouseCoopers and Ernst & Young.
Mr. Hartmann began his career at the U.S. Securities & Exchange Commission's New York Regional Office in 1990.
Path Forward
The Company expects to update its financials, name change and symbol change as soon as possible.
About Optimus
Optimus will focus on acquiring controlling interests in profitable healthcare-related businesses. Between Dandelions Inc. will file for a name change to Optimus Healthcare Services, Inc. as soon as possible.
Safe Harbor Statement Information in this news release may contain statements about future expectations, plans, prospects or performance of Between Dandelions, Inc. that constitute forward-looking statements for purposes of the safe harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Between Dandelions, Inc. cautions you that any forward-looking information provided by or on behalf of Between Dandelions, Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Between Dandelions, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Between Dandelions, Inc.'s control. In addition to those discussed in Between Dandelions, Inc.'s press releases, public filings, and statements by Between Dandelions, Inc.'s management, including, but not limited to, Between Dandelions, Inc.'s estimate of the sufficiency of its existing capital resources, Between Dandelions, Inc.'s ability to raise additional capital to fund future operations, Between Dandelions, Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Between Dandelions, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Between Dandelions, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT:
Optimus HealthCare Services, Inc
Marc Wiener
mwiener@researchcra.com
1-855-737-2873
SOURCE: Between Dandelions, Inc.
View source version on accesswire.com:
https://www.accesswire.com/622457/Between-Dandelions-Inc-Announces-Merger-with-Optimus-Healthcare-Services-Inc
AskMuncher
5年前
$HOPS Between Dandelions, Inc. Announces Merger with Optimus Healthcare Services, Inc.
Press Release | 12/29/2020
NEW YORK, NY / ACCESSWIRE / December 29, 2020 / Between Dandelions Inc (OTC PINK:HOPS) announced today the closing of a merger with Optimus Healthcare Services, Inc. ("Optimus" or "Company").
Optimus, a company formed in 2020, controlled by KORR Acquisitions Group, Inc. ("KORR"), recently acquired control of Clinical Research Alliance, Inc. ("CRA"). Optimus was a portfolio company of KORR and as of the closing, KORR is now the controlling shareholder of Between Dandelions Inc. Between Dandelions Inc. will change its name to Optimus Healthcare Services Inc.
Optimus will focus on healthcare-related services.
The Company has appointed a new CEO, Marc Wiener. Prior to joining Optimus, Mr. Wiener was the founder of Orphan Pharmacy Services, which was sold in 2020, the co-founder of Linden Care Services, which sold to Belhealth Investment Partners in 2013, and Vitality Pharmaceutical Services, which sold to BioScrip in 2002.
Mr. Wiener graduated from St. John's University in 1989 with a degree in Pharmacy.
"I was happy for our shareholders that we had a successful sale our beer assets and were able to distribute a special dividend to our shareholders last year. We have been looking for an opportunity to bring additional value to our shareholders and believe we have done just that in this merger with Optimus. I am excited to work with KORR and the team of CRA," commented Sean Spiegelman.
About Clinical Research Alliance ("CRA")
CRA was founded by Dr. Francis Arena and Dr. Morton Coleman, both of whom are respected as among the top oncologists in the United States. Dr. Coleman and Dr. Arena will continue their affiliation with CRA, and Marc Wiener and industry veteran David Bensol take operational control in CRA's planned expansion.
CRA brings the clinician and patient together for clinical trials - all within the comforts of community-based offices without the stress of travel or changing of doctors, providing pristine clinical data designed to facilitate and advance the treatment of disease. CRA is dedicated to providing our community oncologists the support and vital infrastructure necessary to gather data and administer these studies by our mobile task force of research nurses and clinical research coordinators. This will ensure the ability to provide pristine study data and the appropriate documentation of clinical outcomes in a controlled atmosphere without additional work for your staff. Our proven method of centralized regulatory monitoring and contractual services will expedite the research process resulting in quality data while following the guidelines of Good Clinical Practices.
A centralized uniform approach to the implementation and supervision of clinical trials.
Direct access with your physician office providing the necessary mobile staff
The most dynamic of studies often involving new treatment strategies to combat cancer.
(https://www.clinicalresearchalliance.org/)
CRA is changing the paradigm of how clinical research is done. CRA has multiple research sites throughout the tri-state area (New York, New Jersey, and Connecticut). CRA's list of Alliance physicians and locations of sites continues to grow and expand.
Board of Directors
Effective today, the board of directors for Between Dandelions, Inc. shall include:
Marc Wiener, CEO and board member (see bio above)
Kenneth Orr, Executive Chairman
Mr. Orr is Executive Chairman of the Company and also the Executive Chairman of Charge Enterprises.
Since founding KORR, Mr. Orr has been an activist investor pushing to drive stakeholder value at undervalued public companies. Mr. Orr's most recent activist campaigns include: Sanderson Farms, encouraging the board to engage in a share buyback program, The Andersons, organizing a takeover bid by a partner of KORR for $1.5 billion, Argan Inc., pushing a share buyback and a special dividend rewarding long-term shareholders, GoPro, shifting its sales channel from retail-focused to digital, and Medallion Financial, de-consolidating a trust and issuing unsecured notes.
Mr. Orr acquired Herold Securities in 1994 and renamed the firm First Cambridge Securities ("FCS"). FCS established offices in New York City and Los Angeles. As Chief Executive Officer, Kenny built the firm to over 400 employees with more than 15,000 clients. Notable underwritings and/or investment focuses included Rentway, which later sold to Rent-A-Center in 2003, and Ivax Corporation, which sold to Teva in 2005, creating the largest generic drug manufacturer in the world.
Mr. Orr is a graduate of Tufts University. Mr. Orr completed case studies in finance at Harvard Business School, and value investing at Columbia Business School. Mr. Orr holds a Series 65 - Uniform Investment Advisor Law Exam
Philip Scala, CEO of Pathfinder Consultants International, Inc. ("Pathfinder"). Prior to forming Pathfinder, Mr. Scala served the United States both as a Commissioned Officer in the US Army for five years followed by his service in the New York SWAT Team, followed by 29 years of service with the FBI. Mr. Scala has been the recipient of numerous commendations and awards for outstanding service, notably the FBI Shield of Bravery, as a group commendation, as the SWAT team leader of the Al-Qaeda Bomb Factory Raid, on June 3, 1993. Mr. Scala was selected as a Supervisory Special Agent for the Gambino La Cosa Nostra Squad (C-16). During his tenure, the squad successfully investigated and prosecuted the Mob infiltration of Wall Street, the New York Waterfront investigation, "Murder Incorporated," labor racketeering, the NY Construction Industry, dismantlement of the Gambino family in NY and Sicily, the NBA referee case, and the largest consumers' fraud ($1 billion) in US history, which involved the mob's infiltration of the internet, telecommunications, and banking industries.
James Murphy, CEO of Sutton Associates, a global investigative and research firm. Mr. Murphy is a former Special Agent with the FBI, and former president of Society of Former Special Agents of the Federal Bureau of Investigation. The film, "Dog Day Afternoon" about a bank robbery in 1972 and the 15-hour standoff that followed is based upon Agent Murphy's real life heroism that ended the standoff.
Justin Deutsch has over 20 years in the investment business. He joined Weybosset Research & Management, LLC in October 2014 as a portfolio manager and is responsible for investing over $300 million in investor capital. Prior to joining the firm, he was an equity analyst and trader at Bay Crest Partners for five years. Before Bay Crest, Justin worked as head trader and portfolio manager for Horn Capital Management.
Michael Pruitt founded in 1999, Avenel Financial Group, a boutique merchant banking firm. Mr. Pruitt formed Chanticleer Holdings, now Amergent Hospitality Group, which commenced operations in June 2005 with him as Chairman of the Board of Directors and CEO, roles he continues to serve today. In January 2011, Mr. Pruitt became a director of the board of Hooters of America, LLC and was early investor/board member in Appalachian Mountain Brewery which was sold to Craft Brew Alliance (Nasdaq:BREW) in 2018. Mr. Pruitt received a Bachelor of Arts degree from Coastal Carolina University in Conway, South Carolina, where he played on the 1982 and 83 World Series Baseball teams.
James Hartmann was a Managing Director, Chief Compliance Officer for Arena Investors LP and its private placement broker-dealer, Arena Financial Services LLC. Earlier in his career, Mr. Hartmann served as CCO for Prudential Public Fixed Income, and UBS Alternative & Quantitative Investments. Mr. Hartmann has also worked as an in-house consultant for assurance clients of PricewaterhouseCoopers and Ernst & Young.
Mr. Hartmann began his career at the U.S. Securities & Exchange Commission's New York Regional Office in 1990.
Path Forward
The Company expects to update its financials, name change and symbol change as soon as possible.
About Optimus
Optimus will focus on acquiring controlling interests in profitable healthcare-related businesses. Between Dandelions Inc. will file for a name change to Optimus Healthcare Services, Inc. as soon as possible.
Safe Harbor Statement Information in this news release may contain statements about future expectations, plans, prospects or performance of Between Dandelions, Inc. that constitute forward-looking statements for purposes of the safe harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Between Dandelions, Inc. cautions you that any forward-looking information provided by or on behalf of Between Dandelions, Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Between Dandelions, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Between Dandelions, Inc.'s control. In addition to those discussed in Between Dandelions, Inc.'s press releases, public filings, and statements by Between Dandelions, Inc.'s management, including, but not limited to, Between Dandelions, Inc.'s estimate of the sufficiency of its existing capital resources, Between Dandelions, Inc.'s ability to raise additional capital to fund future operations, Between Dandelions, Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Between Dandelions, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Between Dandelions, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT:
Optimus HealthCare Services, Inc
Marc Wiener
mwiener@researchcra.com
1-855-737-2873
SOURCE: Between Dandelions, Inc.
View source version on accesswire.com:
https://www.accesswire.com/622457/Between-Dandelions-Inc-Announces-Merger-with-Optimus-Healthcare-Services-Inc
makinezmoney
5年前
$HOPS: Merger with Optimus HealthCare Services.
Now $0.85
GO $HOPS
********************************************************************
Between Dandelions, Inc. Announces Merger with Optimus Healthcare Services, Inc.
Press Release | 12/29/2020
NEW YORK, NY / ACCESSWIRE / December 29, 2020 / Between Dandelions Inc (OTC PINK:HOPS) announced today the closing of a merger with Optimus Healthcare Services, Inc. ("Optimus" or "Company").
Optimus, a company formed in 2020, controlled by KORR Acquisitions Group, Inc. ("KORR"), recently acquired control of Clinical Research Alliance, Inc. ("CRA"). Optimus was a portfolio company of KORR and as of the closing, KORR is now the controlling shareholder of Between Dandelions Inc. Between Dandelions Inc. will change its name to Optimus Healthcare Services Inc.
Optimus will focus on healthcare-related services.
The Company has appointed a new CEO, Marc Wiener. Prior to joining Optimus, Mr. Wiener was the founder of Orphan Pharmacy Services, which was sold in 2020, the co-founder of Linden Care Services, which sold to Belhealth Investment Partners in 2013, and Vitality Pharmaceutical Services, which sold to BioScrip in 2002.
Mr. Wiener graduated from St. John's University in 1989 with a degree in Pharmacy.
"I was happy for our shareholders that we had a successful sale our beer assets and were able to distribute a special dividend to our shareholders last year. We have been looking for an opportunity to bring additional value to our shareholders and believe we have done just that in this merger with Optimus. I am excited to work with KORR and the team of CRA," commented Sean Spiegelman.
About Clinical Research Alliance ("CRA")
CRA was founded by Dr. Francis Arena and Dr. Morton Coleman, both of whom are respected as among the top oncologists in the United States. Dr. Coleman and Dr. Arena will continue their affiliation with CRA, and Marc Wiener and industry veteran David Bensol take operational control in CRA's planned expansion.
CRA brings the clinician and patient together for clinical trials - all within the comforts of community-based offices without the stress of travel or changing of doctors, providing pristine clinical data designed to facilitate and advance the treatment of disease. CRA is dedicated to providing our community oncologists the support and vital infrastructure necessary to gather data and administer these studies by our mobile task force of research nurses and clinical research coordinators. This will ensure the ability to provide pristine study data and the appropriate documentation of clinical outcomes in a controlled atmosphere without additional work for your staff. Our proven method of centralized regulatory monitoring and contractual services will expedite the research process resulting in quality data while following the guidelines of Good Clinical Practices.
A centralized uniform approach to the implementation and supervision of clinical trials.
Direct access with your physician office providing the necessary mobile staff
The most dynamic of studies often involving new treatment strategies to combat cancer.
(https://www.clinicalresearchalliance.org/)
CRA is changing the paradigm of how clinical research is done. CRA has multiple research sites throughout the tri-state area (New York, New Jersey, and Connecticut). CRA's list of Alliance physicians and locations of sites continues to grow and expand.
Board of Directors
Effective today, the board of directors for Between Dandelions, Inc. shall include:
Marc Wiener, CEO and board member (see bio above)
Kenneth Orr, Executive Chairman
Mr. Orr is Executive Chairman of the Company and also the Executive Chairman of Charge Enterprises.
Since founding KORR, Mr. Orr has been an activist investor pushing to drive stakeholder value at undervalued public companies. Mr. Orr's most recent activist campaigns include: Sanderson Farms, encouraging the board to engage in a share buyback program, The Andersons, organizing a takeover bid by a partner of KORR for $1.5 billion, Argan Inc., pushing a share buyback and a special dividend rewarding long-term shareholders, GoPro, shifting its sales channel from retail-focused to digital, and Medallion Financial, de-consolidating a trust and issuing unsecured notes.
Mr. Orr acquired Herold Securities in 1994 and renamed the firm First Cambridge Securities ("FCS"). FCS established offices in New York City and Los Angeles. As Chief Executive Officer, Kenny built the firm to over 400 employees with more than 15,000 clients. Notable underwritings and/or investment focuses included Rentway, which later sold to Rent-A-Center in 2003, and Ivax Corporation, which sold to Teva in 2005, creating the largest generic drug manufacturer in the world.
Mr. Orr is a graduate of Tufts University. Mr. Orr completed case studies in finance at Harvard Business School, and value investing at Columbia Business School. Mr. Orr holds a Series 65 - Uniform Investment Advisor Law Exam
Philip Scala, CEO of Pathfinder Consultants International, Inc. ("Pathfinder"). Prior to forming Pathfinder, Mr. Scala served the United States both as a Commissioned Officer in the US Army for five years followed by his service in the New York SWAT Team, followed by 29 years of service with the FBI. Mr. Scala has been the recipient of numerous commendations and awards for outstanding service, notably the FBI Shield of Bravery, as a group commendation, as the SWAT team leader of the Al-Qaeda Bomb Factory Raid, on June 3, 1993. Mr. Scala was selected as a Supervisory Special Agent for the Gambino La Cosa Nostra Squad (C-16). During his tenure, the squad successfully investigated and prosecuted the Mob infiltration of Wall Street, the New York Waterfront investigation, "Murder Incorporated," labor racketeering, the NY Construction Industry, dismantlement of the Gambino family in NY and Sicily, the NBA referee case, and the largest consumers' fraud ($1 billion) in US history, which involved the mob's infiltration of the internet, telecommunications, and banking industries.
James Murphy, CEO of Sutton Associates, a global investigative and research firm. Mr. Murphy is a former Special Agent with the FBI, and former president of Society of Former Special Agents of the Federal Bureau of Investigation. The film, "Dog Day Afternoon" about a bank robbery in 1972 and the 15-hour standoff that followed is based upon Agent Murphy's real life heroism that ended the standoff.
Justin Deutsch has over 20 years in the investment business. He joined Weybosset Research & Management, LLC in October 2014 as a portfolio manager and is responsible for investing over $300 million in investor capital. Prior to joining the firm, he was an equity analyst and trader at Bay Crest Partners for five years. Before Bay Crest, Justin worked as head trader and portfolio manager for Horn Capital Management.
Michael Pruitt founded in 1999, Avenel Financial Group, a boutique merchant banking firm. Mr. Pruitt formed Chanticleer Holdings, now Amergent Hospitality Group, which commenced operations in June 2005 with him as Chairman of the Board of Directors and CEO, roles he continues to serve today. In January 2011, Mr. Pruitt became a director of the board of Hooters of America, LLC and was early investor/board member in Appalachian Mountain Brewery which was sold to Craft Brew Alliance (Nasdaq:BREW) in 2018. Mr. Pruitt received a Bachelor of Arts degree from Coastal Carolina University in Conway, South Carolina, where he played on the 1982 and 83 World Series Baseball teams.
James Hartmann was a Managing Director, Chief Compliance Officer for Arena Investors LP and its private placement broker-dealer, Arena Financial Services LLC. Earlier in his career, Mr. Hartmann served as CCO for Prudential Public Fixed Income, and UBS Alternative & Quantitative Investments. Mr. Hartmann has also worked as an in-house consultant for assurance clients of PricewaterhouseCoopers and Ernst & Young.
Mr. Hartmann began his career at the U.S. Securities & Exchange Commission's New York Regional Office in 1990.
Path Forward
The Company expects to update its financials, name change and symbol change as soon as possible.
About Optimus
Optimus will focus on acquiring controlling interests in profitable healthcare-related businesses. Between Dandelions Inc. will file for a name change to Optimus Healthcare Services, Inc. as soon as possible.
Safe Harbor Statement Information in this news release may contain statements about future expectations, plans, prospects or performance of Between Dandelions, Inc. that constitute forward-looking statements for purposes of the safe harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Between Dandelions, Inc. cautions you that any forward-looking information provided by or on behalf of Between Dandelions, Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Between Dandelions, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Between Dandelions, Inc.'s control. In addition to those discussed in Between Dandelions, Inc.'s press releases, public filings, and statements by Between Dandelions, Inc.'s management, including, but not limited to, Between Dandelions, Inc.'s estimate of the sufficiency of its existing capital resources, Between Dandelions, Inc.'s ability to raise additional capital to fund future operations, Between Dandelions, Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Between Dandelions, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Between Dandelions, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT:
Optimus HealthCare Services, Inc
Marc Wiener
mwiener@researchcra.com
1-855-737-2873
SOURCE: Between Dandelions, Inc.
View source version on accesswire.com:
https://www.accesswire.com/622457/Between-Dandelions-Inc-Announces-Merger-with-Optimus-Healthcare-Services-Inc
Investor TwoPointO
7年前
I copied and pasted the information below:
OTC Pink Basic Disclosure Statement September 30, 2018
Number of Shares Beneficially Owned and Percentage
Sean Spiegelman
7,200,000 Common 89.57%
1,000,000 Preferred B 11.9%
9,998,889 Preferred A 99.9%
A) Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer’s executive officers, directors, general partners and control persons (control
persons are beneficial owners of more than five percent (5%) of any class of the issuer’s equity securities), as of the date of this information statement.
1. Sean Spiegelman – Executive Officer, Director and Control
2. Stephanie Spiegelman – Control
3. Nathan Kelischek – Control
4. Fordee CA Trust – Control
5. Qualstar Capital Corp. – Control
6. Clinton Walker - Control
In my opinion, I believe the dividend of $.34/share will happen because it gives our CEO and others a ton of money in their pockets, which includes us shareholders. So those of us lucky enough to accumulate some shares at anything under $2.00/share are gonna make some money by end of month. I also believe that the "Control" people are mostly all Preferred B Shareholders, which says in the PR are eligible for the dividend, but does not give any details. Either way, again in my opinion, I believe we the shareholders will be getting paid.
HOPS Long $$$$
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Renee
5年前
Golden Cross
5年前
stock1ace1
5年前
IPO$
7年前
funnyG986
7年前
Huggy Bear
7年前
メールアドレスで登録
